Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist

JCI Insight(2020)10.1172/jci.insight.140532Source: DataRank Database

Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist is a research paper published in JCI Insight (2020). On theSindex it has a DataRank of 0. It has been cited 501 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access501 citations

Download PDF

Cite:

Linked data & code

gen nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (11 grants)Impact (FWCI 35.42)OA: goldTopics (72)Linked Datasets (6)DataCite Reuse (6)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (18)

Jonathan D. Douros ORCID,M Gabe ORCID,Aaron D. Showalter,David B. Wainscott ORCID,Todd M. Suter

Live enrichment

PubMed:32730231 PMC:PMC7526454 OpenAlex:https://openalex.org/W3045729180

NIH Clinical Center

Grant: F32 DK116542,1-18-JDF-017,R01 DK123075,R01 DK101991

NNF Center for Basic Metabolic Research

Grant: Holst Group

NIDDK NIH HHS

Grant: F32 DK115031

NIDDK NIH HHS

Grant: T32 DK007012

NIDDK NIH HHS

Grant: F32 DK116542

NIDDK NIH HHS

Grant: R01 DK101991

NIDDK NIH HHS

Grant: R01 DK123075

National Institutes of Health

Grant: 1F32DK115031-01

Assessing the Role of Glucose-Dependent Insulinotropic Polypeptide to Mediate Improved Beta-Cell Function Following Bariatric Surgery

National Institutes of Health

Grant: 5F32DK116542-03

The Role of Islet DPP4 for Regulation of Glucose Homeostasis

National Institutes of Health

Grant: 5R01DK123075-03

Mechanisms of insulin secretion mediated by alpha cells

National Institutes of Health

Grant: 5R01DK101991-05

Incretin Action in Physiology and Diabetes

FWCI

35.42

Citation Percentile

1.0%

Citation Trend

2020

2021

2022

2023

2024

2025

2026

goldLicense: cc-by

journalhttp://insight.jci.org/articles/view/140532/files/pdf

publisherhttp://insight.jci.org/articles/view/140532/files/pdf

publisherhttps://insight.jci.org/articles/view/140532/files/pdf

journalhttps://doi.org/10.1172/jci.insight.140532

repositoryhttps://pubmed.ncbi.nlm.nih.gov/32730231

Fields of Study

Pancreatic function and diabetesDiabetes Treatment and ManagementReceptor Mechanisms and Signaling0301 basic medicine03 medical and health sciences0303 health sciencesAnimalsBlood GlucoseGastric Inhibitory PolypeptideHypoglycemic AgentsInsulinIslets of LangerhansMaleMiceMice, KnockoutReceptors, Gastrointestinal Hormonebeta-Arrestin 1TirzepatideGlucagon-Like Peptide-1 Receptor Agonists

MeSH Terms

Glucagon-Like Peptide-1 Receptorbeta-Arrestin 1Glucagon-Like Peptide-1 Receptor AgonistsTirzepatideAnimalsBlood GlucoseGastric Inhibitory PolypeptideHypoglycemic AgentsInsulinIslets of LangerhansMaleReceptors, Gastrointestinal HormoneMice, KnockoutMice

Keywords

AgonistGlucagon-like peptide 1 receptorReceptorLiraglutideG protein-coupled receptorEndocrinologyInternal medicineFunctional selectivityPharmacologyType 2 diabetesMedicineBiologyDiabetes mellitusDiabetesTherapeuticsBlood GlucoseMaleDEPENDENT INSULINOTROPIC POLYPEPTIDEGastric Inhibitory PolypeptideTirzepatideReceptors, Gastrointestinal HormoneACTIVATIONIslets of LangerhansMiceSERUM-PROTEIN BINDINGAnimalsHypoglycemic AgentsInsulinAFFINITYMice, KnockoutGLUCAGON-LIKE PEPTIDE-1DULAGLUTIDERIN-VITRObeta-Arrestin 1Glucagon-Like Peptide-1 Receptor AgonistsINHIBITORSSEMAGLUTIDEResearch Article

Sustainable Development Goals

SDG 0: Good health and well-being

Additional file 1 of Efficacy and safety of tirzepatide, dual GLP-1/GIP receptor agonists, in the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials

10.6084/m9.figshare.26633796.v1figshare

Additional file 1 of Efficacy and safety of tirzepatide, dual GLP-1/GIP receptor agonists, in the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials

10.6084/m9.figshare.26633796figshare

Additional file 1 of Tirzepatide prevents neurodegeneration through multiple molecular pathways

10.6084/m9.figshare.26674158.v1figshare

Additional file 1 of Tirzepatide prevents neurodegeneration through multiple molecular pathways

10.6084/m9.figshare.26674158figshare

Additional file 1 of Evidence that tirzepatide protects against diabetes-related cardiac damages

10.6084/m9.figshare.26699858.v1figshare

Additional file 1 of Evidence that tirzepatide protects against diabetes-related cardiac damages

10.6084/m9.figshare.26699858figshare